RU2006117639A - Комбинированное лечение ожирения с привлечением производных 4, 5-дигидро-1н-пиразола, обладающих антагонистической активностью по отношению к св1, и ингибиторов липазы - Google Patents

Комбинированное лечение ожирения с привлечением производных 4, 5-дигидро-1н-пиразола, обладающих антагонистической активностью по отношению к св1, и ингибиторов липазы Download PDF

Info

Publication number
RU2006117639A
RU2006117639A RU2006117639/15A RU2006117639A RU2006117639A RU 2006117639 A RU2006117639 A RU 2006117639A RU 2006117639/15 A RU2006117639/15 A RU 2006117639/15A RU 2006117639 A RU2006117639 A RU 2006117639A RU 2006117639 A RU2006117639 A RU 2006117639A
Authority
RU
Russia
Prior art keywords
compound
antagonist
group
treatment
obesity
Prior art date
Application number
RU2006117639/15A
Other languages
English (en)
Russian (ru)
Inventor
Йохен АНТЕЛЬ (DE)
Йохен Антель
Хайнц Гюнтер КРАУЗЕ (DE)
Хайнц Гюнтер КРАУЗЕ
Петер-Колин ГРЕГОРИ (DE)
Петер-Колин Грегори
Михаэль ВУРЛЬ (DE)
Михаэль ВУРЛЬ
Харальд ВАЛЬДЕКК (DE)
Харальд ВАЛЬДЕКК
Йосефус-Хубертус-Мари ЛАНГЕ (NL)
Йосефус-Хубертус-Мария ЛАНГЕ
Корнелис Геррит КРУСЕ (NL)
Корнелис Геррит КРУСЕ
Original Assignee
Зольвай Фармасьютиклз Гмбх (De)
Зольвай Фармасьютиклз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зольвай Фармасьютиклз Гмбх (De), Зольвай Фармасьютиклз Гмбх filed Critical Зольвай Фармасьютиклз Гмбх (De)
Publication of RU2006117639A publication Critical patent/RU2006117639A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2006117639/15A 2003-10-24 2004-10-22 Комбинированное лечение ожирения с привлечением производных 4, 5-дигидро-1н-пиразола, обладающих антагонистической активностью по отношению к св1, и ингибиторов липазы RU2006117639A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03103961.3 2003-10-24
EP03103961 2003-10-24

Publications (1)

Publication Number Publication Date
RU2006117639A true RU2006117639A (ru) 2007-12-10

Family

ID=34486362

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006117639/15A RU2006117639A (ru) 2003-10-24 2004-10-22 Комбинированное лечение ожирения с привлечением производных 4, 5-дигидро-1н-пиразола, обладающих антагонистической активностью по отношению к св1, и ингибиторов липазы

Country Status (13)

Country Link
EP (1) EP1680106B1 (https=)
JP (1) JP2007509110A (https=)
CN (2) CN1921849A (https=)
AR (1) AR046132A1 (https=)
AT (1) ATE438394T1 (https=)
AU (1) AU2004283055A1 (https=)
BR (1) BRPI0415463A (https=)
CA (1) CA2543342A1 (https=)
DE (1) DE602004022445D1 (https=)
MX (1) MXPA06004390A (https=)
RU (1) RU2006117639A (https=)
TW (1) TW200528102A (https=)
WO (1) WO2005039566A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080039996A (ko) * 2005-08-17 2008-05-07 솔베이 파머슈티컬스 게엠베하 칼륨 채널 억제 화합물의 사용 방법
CN102731418B (zh) * 2012-07-15 2015-03-11 浙江大学 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
CN113166068B (zh) * 2018-11-20 2024-08-16 上海科技大学 MmpL3抑制剂、组合物及其用途
CN117551046B (zh) * 2023-11-17 2025-10-28 广东药科大学附属第一医院 二氨基脲类hsl抑制剂、制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3335A1 (fr) * 2000-03-23 2001-09-27 Solvay Pharm Bv Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1
PL363751A1 (en) * 2001-03-22 2004-11-29 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
KR100903760B1 (ko) * 2001-09-21 2009-06-19 솔베이 파마슈티칼스 비. 브이 Cb1-길항 작용을 가지는 신규한4,5-디하이드로-1h-피라졸 유도체
IL157704A0 (en) * 2001-09-21 2004-03-28 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity
SE0104330D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
RU2344132C2 (ru) * 2003-06-20 2009-01-20 Ф.Хоффманн-Ля Рош Аг 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
MXPA06002064A (es) * 2003-10-20 2006-05-19 Solvay Pharm Bv Derivados e 1h imidazol como moduladores del receptor cannabinoide.
MXPA06004434A (es) * 2003-10-24 2006-06-20 Solvay Pharm Gmbh Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos.

Also Published As

Publication number Publication date
JP2007509110A (ja) 2007-04-12
CA2543342A1 (en) 2005-05-06
EP1680106B1 (en) 2009-08-05
DE602004022445D1 (de) 2009-09-17
BRPI0415463A (pt) 2006-12-19
TW200528102A (en) 2005-09-01
EP1680106A1 (en) 2006-07-19
AU2004283055A1 (en) 2005-05-06
CN1997364A (zh) 2007-07-11
WO2005039566A1 (en) 2005-05-06
ATE438394T1 (de) 2009-08-15
AR046132A1 (es) 2005-11-23
MXPA06004390A (es) 2006-06-14
CN1921849A (zh) 2007-02-28

Similar Documents

Publication Publication Date Title
RU2401658C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
RU2407532C9 (ru) Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток
JP2023545396A5 (https=)
DK1119567T3 (da) Quinazolinderivater
RU2007134380A (ru) Антибактериальные производные пиперидина
EA200400432A1 (ru) Производные мочевины
JP2005501120A5 (https=)
CA2443918A1 (en) Visual function disorder improving agents containing rho kinase inhibitors
RU2017144495A (ru) Противогельминтные депсипептидные соединения
RU2000105266A (ru) Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца
SI9620136B (en) Substituted n-/(aminoiminomethyl or aminomethyl)phenyl/-propyl amides
RU2008126245A (ru) Комбинация ингибитора асне и антагониста 5-нт для лечения когнитивной дисфункции
EA201270266A1 (ru) Гетероциклические соединения
CA2423631A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
CA2553704A1 (en) Substituted benzimidazoles and their use for inducing apoptosis
RU2003109440A (ru) Производные 5-амидино-2-гидроксибензолсульфонамида, содержащие их фармацевтические композиции и промежуточные продукты для их получения
RU2006117639A (ru) Комбинированное лечение ожирения с привлечением производных 4, 5-дигидро-1н-пиразола, обладающих антагонистической активностью по отношению к св1, и ингибиторов липазы
RU2006117627A (ru) Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений
RU2006104024A (ru) Каппа-агонисты, в особенности для лечения и/или профилактики синдрома раздраженной толстой кишки
RU2006138864A (ru) Ингибиторы митотического кинезина
RU2008127260A (ru) Производные хиназолинона в качестве антагонистов ваниллоидов
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
WO2002068399B1 (fr) Derives d'arylcarbamates, preparation et utilisations
US20090304634A1 (en) Novel Combinations